Case report reviews possible autoimmune hypoparathyroidism after SARS-CoV-2 infection in a young adult

Photo by Pawel Czerwinski / Unsplash

Frontiers in Medicine Published May 25, 2026 Medically reviewed May 25, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider extended follow-up and autoimmune evaluation for hypocalcemia after COVID-19.

This case report with literature review describes a young adult Chinese woman with no history of neck surgery who developed hypoparathyroidism and hypocalcemia after SARS-CoV-2 infection. The sample size included one case plus 14 previously published reports reviewed. The intervention or exposure was SARS-CoV-2 infection, and the follow-up duration was more than two years.

The main results showed that PTH levels were persistently suppressed. The etiology of hypoparathyroidism may have an autoimmune contribution possible, given the presence of Hashimoto's thyroiditis. The primary outcome was not reported. Safety data regarding adverse events, serious adverse events, discontinuations, or tolerability were not reported.

Limitations include that baseline calcium and PTH data prior to infection were unavailable. The observation remains preliminary. No cases originating from China were identified in the reviewed literature. The practice relevance underscores the need for extended follow-up in patients presenting with hypocalcemia and blunted PTH responses after COVID-19. Comprehensive autoimmune evaluation and genetic testing should be considered.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Beyond its predominant respiratory involvement, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has also been implicated in endocrine dysfunction. Hypocalcemia is common in Coronavirus Disease 2019 (COVID-19), yet the insufficient compensatory rise in parathyroid hormone (PTH) and its long-term outcomes remain poorly characterized. We describe a young adult Chinese woman with no history of neck surgery who developed severe symptomatic hypocalcemia shortly after acute SARS-CoV-2 infection. Laboratory evaluation revealed inappropriately low PTH levels with concomitant hyperphosphatemia, consistent with hypoparathyroidism (HypoPT). Although baseline calcium/PTH data prior to infection were unavailable, the regular calcium and vitamin D supplementation, along with serial monitoring over more than two years, demonstrated persistently suppressed PTH secretion, supporting a diagnosis of permanent HypoPT. Thyroid imaging and antibody testing confirmed coexistent Hashimoto’s thyroiditis, raising the possibility of an autoimmune contribution. To contextualize this case, we reviewed 14 previously published reports of COVID-19-associated HypoPT, among which no cases originating from China were identified. Based on available data, it cannot be ruled out that SARS-CoV-2 infection may contribute to the development of new-onset HypoPT in addition to worsening pre-existing conditions. Young-onset patients without a history of surgery—particularly those whose hypocalcemia severity does not clearly parallel the severity of infection—appear to have a higher likelihood of subsequent persistent dysfunction, though this observation remains preliminary. This case, together with the literature, underscores the need for extended follow-up in patients presenting with hypocalcemia and blunted PTH responses after COVID-19. Comprehensive autoimmune evaluation and, where appropriate, genetic testing should be considered to clarify etiology and guide long-term management.